Core Insights - Moleculin Biotech has enrolled the 45th subject in its pivotal Phase 2B/3 MIRACLE trial, evaluating Annamycin in combination with cytarabine for treating relapsed or refractory acute myeloid leukemia (R/R AML), marking a significant milestone for the company [1][2] - The upcoming interim data unblinding is expected in mid-2026 and is viewed as a potential inflection point for the company, with preliminary results indicating a 40% remission rate among the first 30 patients [2][3] Trial Progress - The MIRACLE trial is designed to evaluate AnnAraC across eight countries, with an initial dataset expected to include approximately 30 patients treated with AnnAraC and 15 patients in the control arm [2][4] - The trial's adaptive design aims to support a streamlined global registration pathway, integrating Phase 2B data into the Phase 3 portion, in line with regulatory guidance [4] Efficacy and Safety - Preliminary results from the trial show a composite complete remission rate of 40%, with 30% achieving complete remission and 10% achieving complete remission with partial hematologic recovery, despite many patients having previously failed venetoclax-based therapies [3][5] - The absence of cardiotoxicity in over 100 patients treated to date is a notable achievement for the company [2][5] Future Outlook - The company is advancing toward a total enrollment of 90 subjects, with the completion of Part A of the MIRACLE trial expected in Q3 2026 [2][4] - The successful outcomes from the trial could lead to a potential accelerated approval pathway based on the primary endpoint of complete remission [4][5]

Core Insights - Tarsus Pharmaceuticals has achieved a $15 million milestone payment following the regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of China [1][3] - The approval was secured by Grand Pharmaceutical Group Limited, Tarsus' exclusive partner for the development and commercialization of TP-03 in Greater China, which includes China, Hong Kong, Macau, and Taiwan [2] - TP-03 is the first and only therapy approved to address the root cause of Demodex blepharitis, benefiting over 40 million people in the region [3] Company Overview - Tarsus Pharmaceuticals focuses on advancing treatments in eye care, dermatology, and infectious disease prevention, with XDEMVY being FDA approved for Demodex blepharitis [4] - The company is also developing TP-04 for ocular rosacea and TP-05 as an oral tablet for Lyme disease prevention, both currently in Phase 2 trials [4] Financial and Partnership Details - Under the agreement with Grand Pharma, Tarsus is eligible for the $15 million milestone payment based on regulatory approval and patent issuance for TP-03, with further payments contingent on additional regulatory milestones and sales thresholds in China [3]

Core Insights - Talphera, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its NEPHRO CRRT clinical study and financial position [1][2][3] Financial Performance - The company reported a net loss of $3.8 million for Q4 2025, equating to $0.06 per share, compared to a net loss of $1.9 million or $0.07 per share in Q4 2024 [4][14][18] - Total operating costs and expenses for Q4 2025 were $3.5 million, up from $3.0 million in Q4 2024, primarily due to increased R&D and G&A expenses [4][14][20] - Cash and investments stood at $20.4 million as of December 31, 2025, a significant increase from $8.9 million at the end of 2024 [4][19] Clinical Development - Talphera achieved a 50% enrollment milestone in the NEPHRO CRRT study, with 35 patients enrolled out of a target of 70 [2][4][11] - All 12 clinical sites are now operational for patient enrollment, which is expected to accelerate the study's completion by 2026 [1][4] - The NEPHRO CRRT study aims to evaluate the efficacy of Niyad, a formulation of nafamostat, as an anticoagulant in patients undergoing renal replacement therapy [10][11] Future Guidance - The company anticipates cash operating expenses in the range of $17 million to $18 million for 2026, driven by the NEPHRO CRRT study and related expenses [3][5] - A virtual investor and analyst day is scheduled for March 23, 2026, to provide updates on the company's progress and insights from principal investigators involved in the NEPHRO CRRT study [1][6]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has successfully closed a public offering, raising approximately $10 million to fund its research and development activities, particularly for its Phase 3 trial of brilaroxazine in schizophrenia [1][3]. Group 1: Offering Details - The company offered 6,666,667 shares of common stock along with Series G and Series H warrants, each with an exercise price of $1.50 per share [1][2]. - The Series G Warrants are exercisable immediately and expire five years from the issuance date, while the Series H Warrants are also exercisable immediately but expire 12 months from the issuance date [2]. Group 2: Use of Proceeds - The net proceeds from the offering, combined with existing cash and cash equivalents, will be used to fund research and development activities, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, as well as for working capital and other general corporate purposes [3]. Group 3: Financial Position - Following the offering, the company has approximately $23 million in cash and cash equivalents, which is expected to fund operations into Q1-2027 [4]. Group 4: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes brilaroxazine and RP1208 [7].

Core Insights - NewAmsterdam Pharma is presenting data on obicetrapib, a novel oral low-dose therapy for hypercholesterolemia, at the American College of Cardiology Annual Scientific Session [1] Group 1: Presentation Details - The presentation titled "CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial" will take place on March 28, 2026 [2] - Another presentation titled "Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis" is scheduled for March 29, 2026 [2] - A third presentation titled "Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles" will occur on March 30, 2026 [2] Group 2: About Obicetrapib - Obicetrapib is a CETP inhibitor developed to address limitations of current LDL-lowering treatments, showing statistically significant LDL-lowering effects in multiple Phase 2 and Phase 3 trials [3] - The Phase 3 PREVAIL trial, assessing obicetrapib's potential to reduce major adverse cardiovascular events (MACE), completed enrollment with over 9,500 patients [3] - Commercialization rights for obicetrapib in Europe have been granted to the Menarini Group [3] Group 3: About NewAmsterdam - NewAmsterdam Pharma focuses on improving patient care for metabolic diseases where existing therapies are inadequate or poorly tolerated [4] - The company is investigating obicetrapib as a once-daily CETP inhibitor, either alone or in combination with ezetimibe, for patients at risk of cardiovascular disease [4]

Core Insights - Kali Therapeutics has signed a licensing agreement with Sanofi to develop an experimental treatment for autoimmune diseases, specifically KT501 [1][2] Group 1: Licensing Agreement Details - Sanofi will acquire global rights to KT501, a tri-specific antibody developed using Kali Therapeutics' proprietary platform [2] - Kali Therapeutics will receive $180 million in upfront and near-term payments, with potential for up to $1.05 billion in development and commercial milestone payments [2] - The agreement includes tiered royalties on product sales, ranging from high-single digits to double digits if the drug is approved [2] Group 2: Drug Development and Testing - KT501 is currently undergoing early-stage testing in rheumatoid arthritis patients to evaluate its safety and tolerability [3] - Preclinical studies in non-human primates indicated that KT501 significantly reduced B cells while minimizing adverse immune reactions associated with similar treatments [3][4] - The drug is designed to target and modulate immune cells involved in autoimmune disorders, including lupus and rheumatoid arthritis [4] Group 3: Sanofi's Existing Portfolio - Sanofi markets Kevzara, an approved rheumatoid arthritis treatment developed in collaboration with Regeneron Pharmaceuticals, and is also advancing new anti-inflammatory candidates [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - InMed Pharmaceuticals announced new preclinical data showing that INM-901 effectively reduces neuroinflammation in 3D human brain organoid models of Alzheimer's disease [1][11]. Company Overview - InMed Pharmaceuticals is focused on developing a pipeline of proprietary small-molecule drug candidates targeting CB1 and CB2 receptors, with programs in Alzheimer's, ocular, and dermatological indications [16]. Research Collaboration - The studies were conducted in collaboration with Stem Pharm, utilizing their proprietary platform of human neuro-immune organoids, which helps translate animal model results into human-relevant systems [2][3]. Preclinical Findings - INM-901 was evaluated in two distinct human 3D organoid models, demonstrating significant reduction in neuroinflammation and a dose-dependent decrease in pro-inflammatory markers such as IL-6 and IL-8 [4][11]. - The compound showed consistent anti-inflammatory effects across in vivo animal models, ex vivo systems, and human 3D brain organoids, increasing confidence in its potential clinical benefits [6][12]. Future Steps - The company plans to conduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3 2026 and continue IND-enabling pharmacology and toxicology studies [12][18]. - The target is to submit an IND and initiate a Phase 1 clinical trial in 2027, subject to regulatory feedback and completion of necessary studies [18]. Importance of Neuroinflammation - Recent research highlights neuroinflammation as a critical factor in Alzheimer's disease progression, shifting focus from traditional targets like amyloid plaques and tau pathology to inflammation as a strategic therapeutic target [13][14].

Core Insights - The central issue for Venezuelan businesses is the difficulty in obtaining U.S. dollars for importing essential chemicals and ingredients, which is exacerbated by an unfavorable official currency allocation system and ongoing dollar shortages [1][5]. Group 1: Business Challenges - Many Venezuelan business owners face significant hurdles in restocking goods due to uncertainty in foreign currency availability and fluctuating exchange rates, leading to inflation eroding the value of local currency [2]. - A survey indicated that 58% of medium-sized business owners identified the lack of foreign currency as a major obstacle to production [4]. - Businesses are increasingly resorting to unofficial markets for currency, which results in higher costs for imported goods and subsequently increased prices for medications [3][7]. Group 2: Economic Context - Sanctions have severely restricted Venezuelan banks' access to the global financial system, complicating international transactions and payments [5]. - Despite increased oil sales and potential economic stabilization, analysts noted that the availability of dollars for auction has decreased, with recent auctions totaling $1.3 billion, a 13% decline compared to the same period in the previous year [6].

Group 1 - Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine following a late-stage trial [1] - The Phase 3 study showed over 70% efficacy in preventing Lyme disease in individuals aged 5 and older [2] - The primary endpoint did not meet the predetermined statistical significance criterion [2]